Telaprevir: pharmacokinetics and drug interactions.

Article Details

Citation Copy to clipboard

Garg V, Kauffman RS, Beaumont M, van Heeswijk RP

Telaprevir: pharmacokinetics and drug interactions.

Antivir Ther. 2012;17(7):1211-21. doi: 10.3851/IMP2356. Epub 2012 Sep 7.

PubMed ID

22954756 [ View in PubMed

]

Abstract

Telaprevir is an inhibitor of the HCV NS3/4A protease. When used in combination with pegylated interferon and ribavirin, telaprevir has demonstrated a substantial increase in sustained virological response compared with pegylated interferon and ribavirin used alone. Telaprevir has good oral bioavailability, which is enhanced when administered with food. Telaprevir is extensively metabolized and primarily eliminated via faeces. No dose adjustment of telaprevir is needed in patients with mild to severe renal impairment or mild liver impairment. Telaprevir is a substrate and inhibitor of cytochrome P450 3A and P-glycoprotein and, thus, might interact with coadministered drugs that affect or are affected by these metabolic/transport pathways. This article reviews the pharmacokinetic and drug interaction profile of telaprevir.

DrugBank Data that Cites this Article

Drugs

Telaprevir

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Telaprevir	Alpha-1-acid glycoprotein 1	Protein	Humans	No	Substrate	Details
Telaprevir	Serum albumin	Protein	Humans	No	Substrate	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software
Telaprevir Amprenavir	The serum concentration of Telaprevir can be decreased when it is combined with Amprenavir.
Telaprevir Fosamprenavir	The serum concentration of Telaprevir can be decreased when it is combined with Fosamprenavir.
Zolpidem Telaprevir	The serum concentration of Zolpidem can be decreased when it is combined with Telaprevir.